利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

224 条记录 (耗时 0.036 秒)

    RNF167 AND CASTOR1 AS NOVEL MTOR TARGETS
    1.
    发明申请
    RNF167 AND CASTOR1 AS NOVEL MTOR TARGETS 审中-公开

    公开(公告)号：WO2022132301A1

    公开(公告)日：2022-06-23

    申请号：PCT/US2021/055296

    申请日：2021-10-15

    申请人： UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

    发明人： GAO, Shou-Jiang

    IPC分类号： A61K35/76 ,  A61K35/761 ,  A61K39/00 ,  A61K39/235 ,  A61K39/395 ,  A61K48/00

    摘要： The present subject matter relates to the use of one or more inhibitors to treat a disease, e.g., cancer, in a subject. It is based, at least in part, on the discovery that protein kinase B (AKT) and ring finger protein 167 (RNF 167)-mediated CASTOR1 degradation activates the mammalian target of rapamycin complex 1 (mTORC1) independent of arginine and promotes cancer progression. Accordingly, the presently disclosed subject matter provides for compositions, methods, and kits for treating a subj ect using an RNF 167 inhibitor, an inhibitor that reduces phosphorylation of CASTOR1 at S14, ubiquitination and/or degradation of CASTOR1, or a combination thereof.

    SAFE POTENT SINGLE PLATFORM VACCINE AGAINST TIER 1 SELECT AGENTS AND OTHER PATHOGENS
    7.
    发明申请
    SAFE POTENT SINGLE PLATFORM VACCINE AGAINST TIER 1 SELECT AGENTS AND OTHER PATHOGENS 审中-公开
    安全强力单平台疫苗对抗1级选择剂和其他病原体

    公开(公告)号：WO2018026729A1

    公开(公告)日：2018-02-08

    申请号：PCT/US2017/044741

    申请日：2017-07-31

    申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

    发明人： HORWITZ, Marcus A. ,  JIA, Qingmei

    IPC分类号： A61K39/114 ,  A61K39/235 ,  A61P37/04 ,  C12N1/21

    摘要： A method of immunizing a susceptible host against a pathogen comprising administering to the host a vaccine that comprises an attenuated recombinant live vaccine strain lacking a polynucleotide encoding CapB (LVS AcapB), wherein the LVS AcapB expresses an antigen of at least one pathogen from Table 1; or administering to the host a vaccine that comprises an attenuated Listeria monocytogenes expressing the antigen of the pathogen from Table 1; or administering to the host a prime vaccine and a heterologous booster vaccine where the prime vaccine comprises an attenuated recombinant live vaccine strain lacking a polynucleotide encoding CapB (LVS AcapB), wherein the LVS AcapB expresses an antigen of at least one pathogen from Table 1 and the heterologous booster vaccine comprises an attenuated Listeria monocytogenes expressing the antigen of the pathogen from Table 1.

    摘要翻译： 一种针对病原体免疫易感宿主的方法，包括向宿主施用疫苗，所述疫苗包含缺乏编码CapB的多核苷酸的减毒重组活疫苗菌株（LVS AcapB），其中LVS AcapB表达抗原 的来自表1的至少一种病原体; 或向宿主施用包含表达表1中病原体抗原的减毒单核细胞增生利斯特氏菌的疫苗; 或向宿主施用主疫苗和异源加强疫苗，其中主疫苗包含缺乏编码CapB的多核苷酸的减毒重组活疫苗菌株（LVS AcapB），其中LVS AcapB表达表1中至少一种病原体的抗原，和 异源加强疫苗包含表达表1中病原体抗原的减毒单核细胞增生利斯特氏菌。

    COMPOSITIONS AND METHODS FOR FLAVIVIRUS VACCINATION
    9.
    发明申请
    COMPOSITIONS AND METHODS FOR FLAVIVIRUS VACCINATION 审中-公开
    用于黄病毒疫苗的组合物和方法

    公开(公告)号：WO2018014006A1

    公开(公告)日：2018-01-18

    申请号：PCT/US2017/042269

    申请日：2017-07-14

    申请人： ETUBICS CORPORATION

    发明人： JONES, Frank, R. ,  BALINT, Joseph ,  RICE, Adrian ,  LATCHMAN, Yvette ,  GABITZSCH, Elizabeth

    IPC分类号： A61K39/235 ,  C12N15/861

    摘要： Compositions of a recombinant adenovirus based vector vaccine containing one or more flavivirus antigen genes are disclosed herein. Methods for constructing and producing such vaccines and methods of using these vaccines to generate immune responses against flaviviruses are also described. Compositions described herein allow for vaccinations in subjects with preexisting immunity to adenovirus.

    摘要翻译： 本文公开了含有一种或多种黄病毒抗原基因的基于重组腺病毒的载体疫苗的组合物。 还描述了构建和生产这种疫苗的方法以及使用这些疫苗来产生针对黄病毒的免疫应答的方法。 本文所述的组合物允许在对腺病毒具有预先存在的免疫力的受试者中接种疫苗。